Oligodendroglioma historical perspective
|
Oligodendroglioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Oligodendroglioma historical perspective On the Web |
|
American Roentgen Ray Society Images of Oligodendroglioma historical perspective |
|
Risk calculators and risk factors for Oligodendroglioma historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]Sujit Routray, M.D. [3]
Overview
The term "oligodendroglioma" was first coined by Bailey and Cushing in 1926 following the observation that the tumor cells are morphologically similar to oligodendrocytes. Oligodendroglioma was first described and published by W. E. Carnegie Dickson in 1926. In 2009, NJDS mutation was first identified in the pathogenesis of oligodendroglioma by Kevin Smith. Irradiation of pituitary adenoma was also discovered to be associated with oligodendroglioma by Kevin Smith et al.
Historical Perspective
- The term oligodendrglioma was derived from the Greek words "oligo" meaning few and "dendro" meaning trees
- In 1926, the term "oligodendroglioma" was first coined by Bailey and Cushing following the observation that the tumor cells are morphologically similar to oligodendrocytes[1]
- In 1926, oligodendroglioma was first described and published by W. E. Carnegie Dickson[2]
- In 1926, oligodendrogliomas were first classified and graded in a system devised by Bailey and Cushing, and later revised by Kernohan, Ringertz, and others, and since then, classification and grading of gliomas have evolved over the time
- In 1979, modern classification of gliomas based on the World Health Organization (WHO) Classification of Central Nervous System Tumors was first published and revised four times since then
- In 1997, a Westergaard's study showed that patients younger than 20 years had a median survival of 17.5 years[3]
- In 2009, Oxford Neurosymposium study by Kevin Smith, it was first discovered that there is a 69% correlation between NJDS gene mutation and oligodendroglial tumor initiation[4]
- 2009 ASCO Annual Meeting, suggests that PCV therapy may be superior in efficacy to the newer temozolomide therapy. Median time to progression for patients with 1p19q co-deletion was longer following PCV alone (7.6 years) than with temozolomide alone (3.3 years); median overall survival was also longer with PCV treatment versus temozolomide treatment (not reached, vs. 7.1 years)[5]
- Irradiation of pituitary adenoma was also discovered to be associated with oligodendroglioma by Kevin Smith et al
- As of the 2016 edition of the WHO classification, gliomas are classified based not only on histopathologic appearance but also on well-established molecular parameters
References
- ↑ Hartmann C, von Deimling A (2009). "Molecular pathology of oligodendroglial tumors". Recent Results Cancer Res. 171: 25–49. doi:10.1007/978-3-540-31206-2_2. PMID 19322536.
- ↑ Dickson, WEC (1926), Proceeding of the Section of Neurology of the Royal Society Medicine: Oligodendroglioma of Floor of Third Ventricle, Brain-A journal of neurology, p. 578, retrieved 11/20/2015 Check date values in:
|accessdate=(help) - ↑ Engelhard, Herbert H; Stelea, Ana; Mundt, Arno (2003). "Oligodendroglioma and anaplastic oligodendroglioma:". Surgical Neurology. 60 (5): 443–456. doi:10.1016/S0090-3019(03)00167-8. ISSN 0090-3019.
- ↑ Etiology of oligodendroglioma. Wikipedia. https://en.wikipedia.org/wiki/Oligodendroglioma
- ↑ . doi:10.1200/jco.2009.27.15s.2014. Missing or empty
|title=(help)